We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Banco Bradesco SA (BBD) - free report >>
Carpenter Technology Corporation (CRS) - free report >>
Equity Commonwealth (EQC) - free report >>
Image: Bigstock
New Strong Sell Stocks for August 28th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Allakos Inc. (ALLK - Free Report) is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 20.2% downward over the last 30 days.
Banco Bradesco S.A. (BBD - Free Report) is a provider of banking products and financial services. The Zacks Consensus Estimate for its current year earnings has been revised 12.8% downward over the last 30 days.
Carpenter Technology Corporation (CRS - Free Report) is a manufacturer, fabricator and distributor of specialty metals. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.
Equity Commonwealth (EQC - Free Report) is the owner and operator of a real estate investment trust (REIT) with commercial office properties in the United States. The Zacks Consensus Estimate for its current year earnings has been revised 59.1% downward over the last 30 days.
Aptose Biosciences Inc. (APTO - Free Report) is engaged in discovering and developing personalized therapies addressing unmet medical needs in oncology. The Zacks Consensus Estimate for its current year earnings has been revised 18.5% downward over the last 30 days.
View the entire Zacks Rank #5 List.